Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

Subjects:

Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. by J Mark Ansermino (13958512)

Subjects:

Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

“…Background<p>Hyper-IgM syndrome (HIGM) is a genetic immunodeficiency characterized by elevated to normal IgM levels and decreased IgG, IgA, and IgE. The overlapping clinical presentations of different gene mutations complicate diagnosis and management.…”

Effect of 0.1mM salicylic acid (SA) or hydrogen peroxide (H₂O₂) and salt treatment (0 and 75 mM NaCl) on photosynthetic assimilation (<i>A</i>), stomacal cond... by Amal Bouallegue (21512298)

Subjects:

Effect of 0.1mM salicylic acid (SA) or hydrogen peroxide (H₂O₂) and salt treatment (0 and 75 mM NaCl) on Na⁺, K⁺, Ca²⁺ and Cl... by Amal Bouallegue (21512298)

Subjects:

Effect of 0.1mM salicylic acid (SA) or hydrogen peroxide (H₂O₂) and salt treatment (0 and 75 mM NaCl) on Chlorophyll a (Chla), Chlorophyll B (Chlb), Carotenoi... by Amal Bouallegue (21512298)

Subjects:

Median ± IQR <i>M. plutonius</i> bacterial load (CFU/bee) of newly emerged summer worker bees inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and/or treated... by Midhun Sebastian Jose (19336846)

Comparison of examination test and treatment. by Yueju Cai (20978633)

“…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VOT vs DOTS TB treatment adherence rates. by Stavia Turyahabwe (9925935)

“…TB treatment adherence rates among TB patients using VOT was significantly better (<i>p</i><0.01) than those using DOTS.…”

Box plots showing the taxa that were significantly different between thin and normal cows. by Bhuripit Saraphol (20855573)

Subjects:

Characterization of systolic pulmonary arterial pressure (sPAP) of WT BMP9 in rats. by Tobias G. Schips (21799838)

Subjects:

Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i> by Tobias G. Schips (21799838)

Subjects:

Summary of cell-based assay EC50 results for WT BMP9 and A347E variant. by Tobias G. Schips (21799838)

Subjects:

Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode. by Tobias G. Schips (21799838)

Subjects:

Hemodynamic effects of WT BMP9 in rats. by Tobias G. Schips (21799838)

Subjects:

Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode. by Tobias G. Schips (21799838)

Subjects:

<i>In vivo</i> PK evaluation of WT BMP9 in naïve SD rats. by Tobias G. Schips (21799838)

Subjects: